Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Efaproxiral. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Efaproxiral SCHEMBL1649963 | 0.88 | PPARA (0.54) | ALDH1A1POLBSMN1; SMN2L3MBTL1NLRP3 | |
| SCHEMBL12998270 | 0.88 | ALDH1A1 (0.48) | ALDH1A1POLBSMN1; SMN2L3MBTL1LMNA | |
| Efaproxiral SCHEMBL3768310 | 0.86 | PPARA (0.52) | ALDH1A1SMN1; SMN2L3MBTL1NLRP3MAPT | |
| SCHEMBL14341054 | 0.86 | ALDH1A1 (0.51) | ALDH1A1POLBSMN1; SMN2L3MBTL1LMNA | |
| SCHEMBL12998285 | 0.84 | PPARA (0.53) | ALDH1A1POLBSMN1; SMN2L3MBTL1LMNA | |
| SCHEMBL6357176 | 0.81 | ALDH1A1 (0.44) | ALDH1A1POLBSMN1; SMN2L3MBTL1LMNA | |
| SCHEMBL6355161 | 0.80 | ALDH1A1 (0.46) | ALDH1A1POLBSMN1; SMN2L3MBTL1LMNA | |
| SCHEMBL6356512 | 0.80 | CNR1 (0.41) | ALDH1A1POLBSMN1; SMN2L3MBTL1NLRP3 | |
| SCHEMBL6353457 | 0.80 | ALDH1A1 (0.45) | ALDH1A1POLBSMN1; SMN2L3MBTL1LMNA | |
| SCHEMBL16861099 | 0.79 | MEN1 (0.42) | ALDH1A1L3MBTL1LMNANLRP3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380362-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2022-12-01 | — | — | US | disclosed |
| CN-101134732-B | New method for preparing 2-{4-[[(3,5-dimethylaniline)carbonyl ]methyl]phenoxy}-2-methyl sodium propionate and its crystal in water | JIANGSU SIMCERE PHARM RES CO | 2012-05-23 | — | — | CN | disclosed |
| CN-101134732-B | New method for preparing 2-{4-[[(3,5-dimethylaniline)carbonyl ]methyl]phenoxy}-2-methyl sodium propionate and its crystal in water | JIANGSU SIMCERE PHARM RES CO | 2012-05-23 | — | — | CN | disclosed |
| US-7847120-B2 | Compositions of allosteric hemoglobin modifiers and methods of making the same | VIRGINIA COMMONWEALTH UNIVERSITY INTELLECTUAL PROPERTY FOUNDATION (US) | 2010-12-07 | — | — | US | disclosed |
| CN-101134732-A | New method for preparing 2-{4-[[(3,5-dimethylaniline)carbonyl ]methyl]phenoxy}-2-methyl sodium propionate and its crystal in water | JIANGSU SIMCERE PHARMACEUTICAL (CN) | 2008-03-05 | — | — | CN | disclosed |
| CN-101134732-A | New method for preparing 2-{4-[[(3,5-dimethylaniline)carbonyl ]methyl]phenoxy}-2-methyl sodium propionate and its crystal in water | JIANGSU SIMCERE PHARMACEUTICAL (CN) | 2008-03-05 | — | — | CN | disclosed |
| US-20070293698-A1 | Compositions of Allosteric Hemoglobin Modifiers and Methods of Making the Same | ALLOS THERAPEUTICS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| EP-1745012-A2 | COMPOSITIONS OF ALLOSTERIC HEMOGLOBIN MODIFIERS AND METHODS OF MAKING THE SAME | Allos Therapeutics, Inc. (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005102305-A2 | COMPOSITIONS OF ALLOSTERIC HEMOGLOBIN MODIFIERS AND METHODS OF MAKING THE SAME | ALLOS THERAPEUTICS, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| US-20050239893-A1 | Compositions of allosteric hemoglobin modifiers and methods of making the same | ALLOS THERAPEUTICS, INC. (US) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239893-A1 | Compositions of allosteric hemoglobin modifiers and methods of making the same | HBB, HBZ, HBG2 | ALDH1A1 4008/4885POLB 1892/4885SMN1; SMN2 2445/4885 |
| US-20220380362-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | ALDH1A1 709/4885POLB 432/4885SMN1; SMN2 1532/4885 |
| US-20070293698-A1 | Compositions of Allosteric Hemoglobin Modifiers and Methods of Making the Same | HBB, HBZ, HBG2 | ALDH1A1 4008/4885POLB 1892/4885SMN1; SMN2 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.